IDEXX Laboratories (IDEXX Laboratories) Risk Assessment

View and export this data going back to 1991. Start your Free Trial

What is IDEXX Laboratories Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of IDEXX Laboratories is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of IDEXX Laboratories's Risk Assessment

For the Diagnostics & Research subindustry, IDEXX Laboratories's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IDEXX Laboratories's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Risk Assessment distribution charts can be found below:

* The bar in red indicates where IDEXX Laboratories's Risk Assessment falls into.

IDEXX Laboratories (NAS:IDXX) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

IDEXX Laboratories Risk Assessment Related Terms

Thank you for viewing the detailed overview of IDEXX Laboratories's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

IDEXX Laboratories (IDEXX Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IDEXX Laboratories Inc (NAS:IDXX) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

IDXX:Mexico IX1:Germany I1DX34:Brazil IDXX:Austria

Address

One IDEXX Drive, Westbrook, ME, USA, 04092

Website

https://www.idexx.com

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 40% of its revenue from outside the United States.

Executives

James F Polewaczyk	officer: Corporate Vice President	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan Jay Mazelsky	director, officer: President and CEO	ONE IDEXX DRIVE, WESTBROOK ME 04092
Martin Alexander Smith	officer: Executive Vice President	C/O IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan W Ayers	director, officer: President & CEO	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Michael Lane	officer: Executive Vice President	C/O IDEXX LABORATORIES, INC., WESTBROOK ME 04092
Irene Chang Britt	director	CAMPBELL SOUP COMPANY, ONE CAMPBELL PLACE, CAMDEN NJ 08103
Bruce L. Claflin	director	7035 RIDGE ROAD, HANOVER MD 21076
Samer Abdul Samad	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Stuart Essig	director	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lawrence D Kingsley	director	C/O IDEX CORPORATION, 630 DUNDEE ROAD, NORTHBROOK IL 60062
Asha Collins	director	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
M Anne Szostak	director	C/O TUPPERWARE BRANDS CORP, 14901 S ORANGE BLOSSOM TR, ORLANDO FL 32837
Sharon E. Underberg	officer: EVP, GC & Corporate Secretary	EASTMAN KODAK COMPANY, 343 STATE STREET, ROCHESTER NY 14650
Sophie V. Vandebroek	director	6 OAK MEADOW ROAD, LINCOLN MA 01770
Daniel M Junius	director	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451